Article in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Luis A GonzalezYale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0003-2877-7287
Weichang ZhangVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Hualong BaiVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Ryosuke TaniguchiVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0001-7226-1363
Abhay B RamachandraDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut, United States.ORCID 0000-0001-6275-501X
Daniel G JovinYale School of Medicine, New Haven, Connecticut, United States.
Yuichi OhashiVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Mytien NguyenYale School of Medicine, New Haven, Connecticut, United States.
Carly ThaxtonVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0001-9270-8708
Bogdan YatsulaVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Roberto I Vazquez-PadronDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States.ORCID 0000-0002-9370-276X
Jay D HumphreyVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0003-1011-2025
Kathleen A MartinSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0002-1748-0034
Themis R KyriakidesVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Alan DardikVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0001-5022-7367
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Medical Scientist Training ProgramT32GM136651 · NIGMS · YALE UNIVERSITY · PI BARBARA I KAZMIERCZAK · 2020 to 2026
$16.5M
Manipulating the matrix to improve arteriovenous fistula patencyR01HL144476 · NHLBI · YALE UNIVERSITY · PI Alan Dardik · 2019 to 2026
$5.6M
Adaptive immunity regulates arteriovenous fistula remodelingR01HL162580 · NHLBI · YALE UNIVERSITY · PI Alan Dardik · 2023 to 2026
$3.0M
Regulation of venous remodeling and arteriovenous fistula patency by the matricellular protein Tenascin-CF30HL156469 · NHLBI · YALE UNIVERSITY · PI GONZALEZ, LUIS · 2021 to 2023
$79k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) F30-HL1546469HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL144476HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL162580HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) T32-GM136651NHLBI NIH HHS F30 HL156469NHLBI NIH HHS R01 HL144476NHLBI NIH HHS R01 HL162580NIGMS NIH HHS T32 GM007205NIGMS NIH HHS T32 GM136651
6 · The paper itself
Abstract
End-stage kidney disease (ESKD) impacts over 740,000 individuals in the United States, with many patients relying on arteriovenous fistulae (AVF) for hemodialysis due to superior patency and reduced infections. However, AVF patency is reduced by thrombosis and neointimal hyperplasia, yielding a 1-yr patency of only 40%-50%. We hypothesized that tenascin-C (TNC), a regulator of inflammation and immune responses after injury, also regulates venous remodeling during AVF maturation. AVF were created in wild-type (WT) and
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Sustained tenascin-C expression drives neointimal hyperplasia and promotes aortocaval fistula failure. · full record | Socratic